Factor xi anticoagulants Market Outlook 2026–2035: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief
What This Brief Covers
This Meticulous Next™ brief examines factor XI anticoagulants, the new class of blood thinners that target factor XIa to prevent clots with less bleeding. It tests how far the first approval and the trials of competing molecules move factor XI inhibitors into stroke and atrial fibrillation care by 2035, and what that means for pharma firms, cardiologists and payers.
The first approval has arrived. Bayer announced positive OCEANIC-STROKE results for asundexian on 23 November 2025. In 12,327 patients after a non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack, asundexian 50 mg once daily added to antiplatelet therapy cut ischaemic stroke to 6.2% from 8.4% on placebo, a 26% relative reduction, with major bleeding of 1.9% against 1.7%, a difference that was not significant. China approved the medicine as Sunharbo on 26 October 2026, and the US Food and Drug Administration approved it on 9 November 2026. The conclusion is that a factor XIa inhibitor has now shown stroke prevention without a clear rise in major bleeding, and the class has moved from trials to clinical use in under a year.
The label is narrow. The approval covers secondary prevention after a non-cardioembolic stroke or high-risk transient ischaemic attack with antiplatelet therapy, and it does not cover atrial fibrillation. Bayer lists a price of USD 748.50 for a 30-day supply, and stroke specialists expect cost to be the main limit and early uptake to be slow. The conclusion is that the first market is secondary stroke prevention in specialist centres, and the larger atrial fibrillation and thrombosis markets depend on other trials.
The competing molecules face a mixed record. Milvexian, from Bristol Myers Squibb and Johnson & Johnson, saw its acute coronary syndrome trial fail in August 2026, with its stroke and atrial fibrillation trials due to report around the end of 2026. Novartis holds an injectable factor XI antibody through its purchase of Anthos Therapeutics. The conclusion is that the near term field is narrow, and the next readouts decide whether the class widens beyond stroke.
The brief treats factor XI anticoagulants as a high-impact signal with a nine year horizon to 2035. It identifies which developers, payers and care providers capture value as the class expands. It is a focused 108-page decision brief that presents an indicative trajectory rather than a segmented market model.
| Parameter | Details |
|---|---|
| Forward horizon | 2026–2035 (9 years) |
| Emerging force | Factor XI inhibitors |
| Technology readiness | One approved factor XIa inhibitor in the United States and China, with further trials of milvexian and an injectable antibody ongoing |
| Indicative market size & forecast | The factor XI anticoagulants market, covering oral and injectable factor XI and factor XIa inhibitors prescribed for stroke prevention, atrial fibrillation and thrombosis, and excluding direct oral anticoagulants, warfarin, heparins and antiplatelet medicines, is valued at USD 0.03–0.08 billion in 2026 and is projected to reach USD 2.06–5.50 billion by 2035, at a CAGR of 60% |
| Mainstream inflection | ~2030, when atrial fibrillation and further stroke trial data, payer coverage and guidelines support wider prescribing |
| Signal strength | A positive phase 3 stroke trial and first approvals, against a narrow label, a high price and mixed competitor results |
| Primary beneficiaries | Developers with approved products and positive trials; stroke specialists with a lower-bleeding option; payers with clear coverage criteria |
| Brief length / format | 108 pages · PDF + executive summary deck · instant delivery |
Understanding the Technology
Factor XI is a protein in the clotting cascade that matters for clots inside vessels but less for stopping bleeding after injury. Blocking its active form, factor XIa, aims to prevent stroke and thrombosis with less bleeding than current anticoagulants, which act on factor Xa or thrombin. The conclusion is that the class targets the main weakness of existing anticoagulants, which is bleeding.
Asundexian is a once-daily oral small molecule. In OCEANIC-STROKE, ischaemic stroke fell to 6.2% from 8.4%, disabling stroke to 2.1% from 3.0%, and major bleeding was 1.9% against 1.7%, though gastrointestinal bleeding was higher at 2.7 against 2.1 per 100 patient-years. The conclusion is that the bleeding advantage is clear against more intensive therapy but not absolute, and labelling and monitoring will reflect it.
The class has had setbacks. The milvexian stroke trial at phase II missed its primary endpoint, its acute coronary syndrome trial failed in August 2026, and asundexian did not succeed in an atrial fibrillation trial. The conclusion is that benefit depends on the condition, and results in stroke do not transfer automatically to atrial fibrillation.
The limits are label scope, price, drug interactions and the lack of results in atrial fibrillation. The brief tests each limit against the evidence to 2035.
Market Outlook
The factor XI anticoagulants market, covering oral and injectable factor XI and factor XIa inhibitors prescribed for stroke prevention, atrial fibrillation and thrombosis, and excluding direct oral anticoagulants, warfarin, heparins and antiplatelet medicines, is valued at USD 0.03–0.08 billion in 2026 and is projected to reach USD 2.06–5.50 billion by 2035, at a CAGR of 60%.
The 2026 base rests on oral and injectable factor XI and factor XIa inhibitors prescribed for stroke prevention, atrial fibrillation and thrombosis at current prices, which excludes direct oral anticoagulants, warfarin, heparins and antiplatelet medicines. Growth follows the number of patients on treatment, the share of conditions covered by labels and the net price after rebates.
The forecast is sensitive to results of the milvexian and other trials, regulatory decisions in Europe and Japan, payer coverage and guideline recommendations.
Scenarios
The base case assumes at least one further trial supports a wider label and payers cover the stroke indication, bringing the inflection to 2030 and a 2035 value near the middle of the range. An accelerated case assumes positive atrial fibrillation results and fast payer coverage, moving the inflection to 2028 and lifting the 2035 value to the top of the range. A delayed case assumes further trials fail and cost limits uptake, moving the inflection to 2033 and holding growth at the bottom of the range.
Factors Behind Growth
Growth drivers
- Bleeding risk with current anticoagulants.
- Positive phase 3 stroke prevention results.
- First approvals in the United States and China.
- Large population needing antithrombotic therapy.
Enablers
- Priority review by regulators.
- Once-daily oral dosing.
- Several molecules and modalities in development.
- Specialist stroke centre networks.
Restraints and barriers
- Narrow first label.
- Price and reimbursement.
- Mixed trial results across conditions.
- Drug interactions and liver enzyme findings.
The Forces at Play
The direction of factor XI anticoagulants is set by trial results beyond stroke, regulatory decisions, payer coverage and guideline recommendations.
The brief assesses standards and policy, company and investor funding, technology readiness, product readiness and customer readiness, and rates each force for direction, speed and confidence.
Adoption Outlook
How the shift is likely to unfold across three time horizons.
Asundexian launches in secondary stroke prevention while milvexian and other trials report.
Atrial fibrillation and further stroke results decide whether labels widen.
Factor XI inhibitors hold a defined place beside direct oral anticoagulants.
Latest Strategic Developments
| Date | Development | Type | Significance |
|---|---|---|---|
| Nov 2025 | Bayer reports that asundexian met its primary efficacy and safety endpoints in the phase III OCEANIC-STROKE trial | Trial result | Shows stroke prevention without a significant rise in major bleeding |
| May 2026 | The FDA accepts the asundexian new drug application with Priority Review, and Japan accepts the submission | Regulatory | Starts the first regulatory reviews |
| Jun 2026 | The European Medicines Agency accepts the asundexian marketing authorisation application | Regulatory | Opens the European review |
| Aug 2026 | The milvexian phase III trial in acute coronary syndrome fails | Trial result | Narrows the competitor field |
| Oct 2026 | China approves asundexian as Sunharbo on 26 October | Approval | Gives the first approval of a factor XIa inhibitor |
| Nov 2026 | The FDA approves Sunharbo on 9 November for secondary stroke prevention | Approval | Opens the United States market |
Key Players & Competitive Landscape
The key participants in factor XI anticoagulants include Bayer AG, Bristol-Myers Squibb Company, Johnson & Johnson, Novartis AG, Ionis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Pfizer Inc., Daiichi Sankyo Company, Limited, Sanofi, Teva Pharmaceutical Industries Limited, Viatris Inc., Boston Scientific Corporation, Abbott Laboratories, Medtronic plc, HCA Healthcare, Inc., Cardinal Health, Inc., McKesson Corporation, CVS Health Corporation, The Cigna Group, UnitedHealth Group Incorporated and City Therapeutics, among others.
The brief profiles representative participants in each archetype and assesses which are positioned to lead as the class expands.
Competitive intensity is low today with one approved product and rises with milvexian and other entrants, with entry barriers set by outcome trial size, safety evidence and payer contracting.
| Archetype | Representative players | Position | Outlook |
|---|---|---|---|
| Factor XI developers | Bayer AG, Bristol-Myers Squibb Company, Johnson & Johnson, Novartis AG, Ionis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc. | Factor XI and XIa inhibitors | Complete trials and extend labels |
| Incumbent anticoagulant makers | Pfizer Inc., Daiichi Sankyo Company, Limited, Sanofi, Teva Pharmaceutical Industries Limited, Viatris Inc. | Direct oral anticoagulants, heparins and generics | Defend share on price and familiarity |
| Stroke prevention device makers | Boston Scientific Corporation, Abbott Laboratories, Medtronic plc | Cardiac and stroke devices | Compete with drug options for atrial fibrillation stroke prevention |
| Providers and distributors | HCA Healthcare, Inc., Cardinal Health, Inc., McKesson Corporation | Hospitals and drug distribution | Handle early stroke centre use |
| Payers | CVS Health Corporation, The Cigna Group, UnitedHealth Group Incorporated | Coverage and formularies | Set access and price |
Where value migrates.
In 2026 value sits with the first approved product and stroke centres that prescribe it. By 2030 it moves toward developers with wider labels and toward payers that set coverage by risk. By 2035 it settles with products holding guideline positions in stroke and atrial fibrillation. Margins narrow as competing molecules arrive and generic anticoagulants hold the broad market.
Who Will Win — and Why
The archetypes best positioned to capture value as the shift matures.
Wider labels expand the treated population.
A lower-bleeding option fits recurrent stroke care.
Clear rules direct spend to benefit.
Regulatory Landscape
| Jurisdiction | Milestone | Indicative timing | Effect on adoption |
|---|---|---|---|
| US Food and Drug Administration | Approval of Sunharbo for secondary stroke prevention | November 2026 | Opens the United States market |
| China National Medical Products Administration | Approval of Sunharbo | October 2026 | Gives the first approval of a factor XIa inhibitor |
| European Medicines Agency | Marketing authorisation application accepted | June 2026 | Opens the European review |
| Japan Ministry of Health, Labour and Welfare | Submission accepted | May 2026 | Opens the Japanese review |
| US Food and Drug Administration | New drug application accepted with Priority Review | May 2026 | Starts the United States review |
Investment Signals
Bleeding risk with current anticoagulants, positive stroke results, first approvals and a large treatable population support growth, while the narrow first label, price and reimbursement, mixed results across conditions and drug interactions hold back the pace.
The milvexian stroke and atrial fibrillation readouts, a European decision, a payer coverage ruling or a guideline update would shift the pace. The brief therefore tracks four indicators: trial readouts, regulatory decisions, coverage decisions and prescription volumes.
Launch in stroke, then label expansion, then an established class is the expected order of change.
Questions This Brief Answers
Strategic Implications
- Pharma firms: support specialist launch with access programmes and plan trials in atrial fibrillation and other conditions to widen labels.
- Cardiologists and neurologists: use the new option for recurrent stroke patients who need lower bleeding risk and track gastrointestinal bleeding.
- Payers: define coverage by stroke risk and review it when new trial data arrive.
- Providers and distributors: prepare stroke centre pathways and supply for a new class.
- Investors: weigh launch uptake against the milvexian readouts and the pace of label expansion.
"A blood thinner earns trust by preventing the next clot without causing the next bleed."
Table of Contents
Access & Licensing
A focused foresight brief, priced to circulate. Every option is delivered instantly and backed by analyst support.
every brief